文献速递肾小球疾病

Sparsentan与SGLT2抑制剂联合治疗在IgA肾病试验中的解读

Sparsentan - SGLT2 inhibitor combination therapy in trials of IgA nephropathy.
PubMed 文献 · Nephrol Dial Transplant · 2026-09-11

本文基于SPARTACUS试验和PROTECT开放标签扩展子研究,报告了双重内皮素血管紧张素受体拮抗剂sparsentan与SGLT2抑制剂联合治疗IgA肾病的安全性和疗效。SPARTACUS中,在稳定使用SGLT2i的患者中用sparsentan替代RASi导致尿白蛋白肌酐比持续降低至24周。PROTECT OLE子研究中,在稳定使用sparsentan的患者中加用SGLT2i相比单用sparsentan进一步小幅降低蛋白尿。联合治疗耐受性良好,未出现非预期安全信号。

要点

  • 在稳定SGLT2i治疗基础上用sparsentan替代RASi可显著降低IgA肾病患者白蛋白尿。
  • 在稳定sparsentan治疗基础上加用SGLT2i可进一步小幅降低蛋白尿。
  • sparsentan联合SGLT2i耐受性良好,无意外安全信号。

核心结论

  • 在IgA肾病患者中,用sparsentan替代RASi同时继续稳定SGLT2i治疗导致白蛋白尿显著降低,加用SGLT2i至稳定sparsentan治疗可小幅进一步降低蛋白尿,联合治疗耐受性良好。

研究设计与样本

  • SPARTACUS(NCT05856760)为2期开放标签试验,患者用sparsentan替代RASi并继续稳定SGLT2i,共纳入48例患者,39例完成治疗。
  • PROTECT(NCT03762850)OLE子研究中,接受sparsentan的患者按1:1随机加用SGLT2i或继续sparsentan单药治疗12周,之后所有患者可接受24周sparsentan+SGLT2i联合治疗,共63例患者纳入并完成12周随机治疗。

主要发现

  • SPARTACUS中,在稳定SGLT2i治疗下用sparsentan替代RASi导致尿白蛋白肌酐比快速降低并持续至第24周(最小二乘均值[95%CI]:-56%[-66%至-3%])。
  • PROTECT OLE子研究第12周,sparsentan+SGLT2i组尿蛋白肌酐比较基线的相对变化(最小二乘均值[95%CI])为-11.1%[-26.3%至7.3%],sparsentan单药组为17.7%[-2.4%至42.1%],组间比值[95%CI]为0.75[0.58至0.98],P<0.05。
  • 两项研究中治疗相关不良事件中严重或导致停药的情况较少。

临床怎么用

  • 对于已稳定使用SGLT2i的IgA肾病患者,可考虑用sparsentan替代RASi以进一步降低白蛋白尿。
  • 对于已稳定使用sparsentan的IgA肾病患者,加用SGLT2i可小幅进一步降低蛋白尿,且耐受性良好。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND HYPOTHESIS: Sparsentan, a non-immunosuppressive, dual endothelin angiotensin receptor antagonist (DEARA), and sodium-glucose cotransporter-2 inhibitors (SGLT2is) reduce proteinuria in patients with immunoglobulin A nephropathy (IgAN). We report the safety and efficacy of sparsentan combined with SGLT2is in patients with IgAN in the SPARTACUS trial and a substudy in the PROTECT open-label extension (OLE). METHODS: SPARTACUS (NCT05856760) was a phase 2, open-label trial in which patients had renin-angiotensin system inhibitors (RASi) replaced with sparsentan while continuing stable SGLT2i. In the PROTECT (NCT03762850) OLE substudy, patients receiving sparsentan were randomised 1:1 to add SGLT2i or continue sparsentan alone for 12 weeks; afterward, all could receive 24 weeks of sparsentan+SGLT2i combination therapy. Endpoints in both studies included change in proteinuria and safety. RESULTS: In SPARTACUS, 48 patients were enrolled (mean [SD] age, 48.9 [13.9] y; 58% male); 39 completed treatment. Replacement of RASi with sparsentan while on stable SGLT2i led to rapid urine albumin-to-creatinine ratio reductions sustained through week 24 (least-squares mean [95% CI], -56% [-66% to -3%]). In the PROTECT OLE substudy, 63 patients enrolled and completed the 12-week randomised treatment (sparsentan+SGLT2i [n=32] vs sparsentan alone [n=31]: mean [SD] age, 51.4 [13.4] y vs 50.6 [11.1] y; male 81% vs 68%, respectively); 54 completed 24 weeks of sparsentan+SGLT2i. At week 12, significant relative reductions occurred in the urine protein-to-creatinine ratio (least-squares mean [95% CI]) with sparsentan+SGLT2i (-11.1% [-26.3% to 7.3%]) vs sparsentan alone (17.7% [-2.4% to 42.1%]) (ratio [95% CI], 0.75 [0.58 to 0.98]; P<0.05). Few treatment-related adverse events were severe or serious or led to discontinuation. CONCLUSION: In patients with IgAN, replacing RASi with sparsentan while on stable SGLT2i resulted in marked reductions in albuminuria. Adding SGLT2i to stable sparsentan resulted in modest further reductions in proteinuria. Sparsentan combined with SGLT2i was well tolerated, with no unexpected safety signals.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Ayoub I, Alperovich G, Komers R, et al. Sparsentan - SGLT2 inhibitor combination therapy in trials of IgA nephropathy. Nephrol Dial Transplant. 2026. PMID: 42726023. doi:10.1093/ndt/gfag211

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。